Login to Your Account


Kolltan Pharmaceuticals raises $60M to support cancer trials

By Peter Winter
BioWorld Insight Editor

Wednesday, March 26, 2014
Kolltan Pharmaceuticals Inc., a private company developing monoclonal antibody (MAb) drugs that will target receptor tyrosine kinases, has secured $60 million from a series D financing round, which will help support phase II trials of KTN3379, an inhibitor of the ErbB3 receptor tyrosine kinase, their lead dual-mechanism MAb candidate in cancer patients suffering from various malignancies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription